



27 June 2011

**Immunodiagnostic Systems Holdings plc
("IDS" or "the Company")**

FDA clearance for two new automated assays

Immunodiagnostic Systems Holdings plc, a leading producer of diagnostic testing kits for the clinical and research markets, announces that clearance has been received from the US Food and Drug Administration (FDA) for the Company's IGFBP-3 and CTX-I controls, enabling the related automated assays to be sold in the USA.

This FDA 510(k) clearance brings the total number of automated assays in the IDS-iSYS product range that can be sold in the USA to five. These products are:

25-Hydroxy Vitamin D
hGH (human Growth Hormone)
IGF-I (Insulin-like Growth Factor I)
IGFBP-3 (Insulin-like Growth Factor Binding Protein-3)
CTX-I (C-terminal telopeptide of Type I collagen; CrossLaps®)

The IDS-iSYS product range that can be sold outside the USA currently consists of nine products.

The IGFBP-3 kit completes the IDS-iSYS Growth Panel within the USA. Measurement of IGFBP-3, when used alongside the results obtained using IDS-iSYS hGH and IGF-I assays, is useful in the diagnosis of growth hormone-related disorders and the monitoring of treatment.

CTX-I is a biomarker of bone degradation. The assay is of particular value in identifying individuals with elevated bone resorption and monitoring the efficacy of bone-conserving drugs such as bisphosphonates and denosunab used in the treatment of osteoporotic patients. CTX-I is reimbursed by Medicare in the USA.

Ian Cookson, CEO of IDS, said "The ability to offer the first complete, fully automated Growth Panel in the US meets a clinical need and will further facilitate the placement of IDS-iSYS instruments in specialist laboratories. The availability of CTX-I on the IDS-iSYS in the USA will build on the strong user base already established for the manual version of the assay. These new product additions complement our existing automated products offered on the IDS- iSYS in the USA, our most rapidly growing market."

IDS will announce results for the financial year ended 31 March 2011 on Monday 27 June 2011.

For further information:

Immunodiagnostic Systems Holdings plc
Ian Cookson, Chief Executive Officer
Paul Hailes, Finance Director

Tel: 0191 519 0660

Brewin Dolphin
Matt Davis
Sean Wyndham-Quin

Tel: 0845 213 4930

Walbrook PR Ltd
Paul McManus
Fiona Henson

Tel: 020 7933 8780
paul.mcmanus@walbrookpr.com
fiona.henson@walbrookpr.com